Meal kit company sued by customers who claim ‘contaminated’ lentils led to gallbladders removals

Vegan meal kit startup Daily Harvest has been hit with two lawsuits by customers alleging they needed gallbladder removals after eating one of the company’s products, reportedCNN. Last month the company issued a voluntary recall of its “French Lentil + Leek Crumbles” dish following multiple claims of gastrointestinal and liver from consumers. The first lawsuit was filed by Carol Ann Ready, an Oklahoma woman who is suing the company in the federal court for the Southern District of New York. Ready purchased and ate lentil crumbles from Daily Harvest on two separate occasions in May, both of which both of which resulted in trips to the emergency room. The second of these was a four-day stay, which ended with Ready’s physician recommending gallbladder removal. 

Attorneys for Ready are asking for a jury trial, alleging that damages for the case exceed what the court normally allows. “Plaintiff has sustained serious personal injuries; suffered, and will continue to suffer, significant pain and other physical discomfort; incurred, and will continue to incur, substantial medical expenses; have missed, and will likely miss in the future, work and time necessarily dedicated to advancement in her profession; and remains at risk for future health complications with damages far in excess of $75,000, the jurisdictional threshold of this court,” says the complaint, obtained by Food Safety News.

Earlier this week, an Oregon-based content creator who claimed he also consumed the lentils and subsequently had to have his gallbladder removed filed a personal injury lawsuit against Daily Harvest. In a video posted to Twitter on June 21, the plaintiff in the lawsuit, Luke Wesley Pearson, warned his followers not to eat the lentil crumbles.

Daily Harvest still hasn’t pinpointed what may have caused the adverse reactions. “All pathogen and toxicology results have come back negative so far, but we’re continuing to do extensive testing so we can get to the bottom of this. Everyone who has been affected deserves an answer, and we are committed to making this right,” the company said in a statement to CNN.

Yesterday the FDA announced a formal investigation into the outbreak, in an effort to determine the cause. In a blog post, Daily Harvest said it received approximately 470 reports from customers who suffered adverse reactions after eating the product.

FDA says updated COVID-19 Omicron boosters won’t require new clinical trials

A Food and Drug Administration official said COVID-19 vaccine makers won’t need to carry out fresh clinical trials to receive approval for booster shots they’re updating for newer Omicron variants. Dr. Peter Marks, who runs the FDA’s Center for Biologics Evaluation and Research, told Reuters the agency will use data from trials for vaccines that target BA.1 — the Omicron variant that caused a huge surge in infections last winter — as well as manufacturing data to assess the vaccines. Safety data and preclinical data from animal studies may also be used. 

This week, the FDA asked vaccine manufacturers to modify booster shots to target the Omicron BA.4 and BA.5 variants in addition to the original strain of the virus. The agency hopes the updated boosters will be ready by the fall. “It’s going to be really critical as we move into this fall where we’ve seen this evolution into BA.4/5, where we could see further evolution, to try to get as many people boosted as we can,” Marks said.

The Centers for Disease Control and Prevention says BA.1 isn’t circulating in the US anymore, but BA.4 and BA.5 now account for over 52 percent of COVID-19 infections in the country. Combined, they made up just 0.5 percent of cases in the US at the end of April.

Pfizer and Moderna this week released clinical trial data which suggests versions of their shots that target BA.1 offered a stronger immune response than the initial COVID-19 vaccines. Those boosters did not perform quite as well against BA.4 and BA.5. However, the data showed that the immune response was still robust.

ねっこり on Twitter: “@minnkap000 カンピロバクターはヤバいですよ。うちの母は焼き鳥で食中毒、ギランバレーのひどい方になって、今じゃアイコンタクトしかできない人間になりました。焼き鳥は多分屋台みたいな所で買ったらしく店を特定できませんでした。それ以来、レシート出る店でしか入りません。”

@minnkap000 カンピロバクターはヤバいですよ。うちの母は焼き鳥で食中毒、ギランバレーのひどい方になって、今じゃアイコンタクトしかできない人間になりました。焼き鳥は多分屋台みたいな所で買ったらしく店を特定できませんでした。それ以来、レシート出る店でしか入りません。

FDA asks COVID-19 vaccine makers to update boosters to target new Omicron variants

The Food and Drug Administration has asked COVID-19 vaccine makers to update booster shots to tackle newer Omicron variants that are on the rise. It says the manufacturers should add a spike protein component to shots to target the Omicron BA.4 and BA.5 variants in addition to the original strain.

An “overwhelming majority” of the FDA’s advisory committee voted this week in favor of updating shots with an Omicron component, in the hopes of starting to use those modified boosters in the fall. The advisory is only for booster shots and not primary inoculations.

Vaccine makers are essentially playing whack-a-mole with the various strains of COVID-19. Pfizer and Moderna have created versions of their vaccines that target BA.1, the Omicron variant that caused a significant upswing in COVID-19 cases during the winter.

However, that strain isn’t circulating in the US anymore, according to the Centers for Disease Control and Prevention. Earlier this week, the CDC said BA.4 and BA.5 now account for over 52 percent of COVID-19 infections in the US. That figure is expected to rise in the coming weeks.

As CNBC notes, Pfizer and Moderna released clinical trial data this week showing that the current Omicron shots performed better against BA.1 than the original versions of their vaccines in terms of offering a stronger immune response. While the immune response against BA.4 and BA.5 was still said to be robust, the Omicron inoculations were less effective against those strains. It’s unclear how long it will take vaccine makers to develop shots that take aim at BA.4 and BA.5.

“Vaccine manufacturers have already reported data from clinical trials with modified vaccines containing an Omicron BA.1 component and we have advised them that they should submit these data to the FDA for our evaluation prior to any potential authorization of a modified vaccine containing an Omicron BA.4/5 component,” the FDA said. “Manufacturers will also be asked to begin clinical trials with modified vaccines containing an Omicron BA.4/5 component, as these data will be of use as the pandemic further evolves.”

Facebook and Instagram are blocking posts about mailing abortion pills

If you post about being able to mail abortion pills to those who need it on Facebook or Instagram, don’t be surprised if you get a warning — or even get your account restricted. A tipster told Motherboard that they were notified a minute after posting …

シニアになったら卵は1日1~2個も 塩分、コレステロールは気にし過ぎない

第2回 フレイル対策の食事は「1にカロリー、2にたんぱく質」が鉄則! 2022/6/24 伊藤和弘=ライター 年を取ったらしっかり食べ、むしろ太ったほうが長生き……。そんな「健康の常識」が180度変わる話を、在宅医療のエキスパート、佐々木淳氏に聞いた。要介護状態の前段階ともいえるフレイル(虚弱)のリスクに備えるため…

FDA bans sales of Juul vape products in the US

The Food and Drug Administration has banned e-cigarette maker Juul from selling and distributing its products in the US. It ordered the company to remove its wares from the market or face enforcement actions. 

Reports earlier this week suggested that an FDA ban on Juul products was imminent. After a two-year review, the agency rejected Juul’s application to keep selling tobacco- and menthol-flavored pods, as well as its vape pen. Juul told Engadget that it intends to seek a stay on the decision. It is exploring all other options, including an appeal.

The ban doesn’t apply to Juul products that are already in the possession of the company’s customers. However, it’ll be difficult, if not impossible, to find its pens and pods in the near future.

In 2020, the FDA began a comprehensive review of all e-cigarette products sold in the US. It weighed up the potential benefits of vaping compared with cigarettes for adult smokers against the popularity of e-cigarettes among underage users. The agency has permitted other manufacturers to continue selling vape products, including NJOY and Vuse parent Reynolds American. To date, the agency has authorized 23 “electronic nicotine delivery systems” (to give vape pens their formal name).

In Juul’s case, though, the FDA said the company’s application “lacked sufficient evidence regarding the toxicological profile of the products to demonstrate that marketing of the products would be appropriate for the protection of the public health. In particular, some of the company’s study findings raised concerns due to insufficient and conflicting data – including regarding genotoxicity and potentially harmful chemicals leaching from the company’s proprietary e-liquid pods – that have not been adequately addressed and precluded the FDA from completing a full toxicological risk assessment of the products named in the company’s applications.”

The agency went on to say that it doesn’t have clinical information that suggests there is “an immediate hazard” linked to Juul’s pen or pods. “However, the [marketing denial orders] issued today reflect FDA’s determination that there is insufficient evidence to assess the potential toxicological risks of using the Juul products,” the FDA said. It noted that it’s not possible to grasp the possible harms of using other pods in a Juul vape pen or the company’s pods in third-party devices.

“The FDA is tasked with ensuring that tobacco products sold in this country meet the standard set by the law, but the responsibility to demonstrate that a product meets those standards ultimately falls on the shoulders of the company,” said Michele Mital, acting director of the FDA’s Center for Tobacco Products. “As with all manufacturers, Juul had the opportunity to provide evidence demonstrating that the marketing of their products meets these standards. However, the company did not provide that evidence and instead left us with significant questions. Without the data needed to determine relevant health risks, the FDA is issuing these marketing denial orders.”

The company became the leader in the US e-cigarette market in 2018. However, sales have dropped following a string of controversies. Juul slipped to second place behind Vuse in terms of US market share. The vast majority of the company’s revenue comes from the US, The Wall Street Journal noted this week. 

Juul had been accused by federal agencies, state attorneys general and other officials of marketing its products to teens. The company agreed to pay eight-figure settlements related to lawsuits in North Carolina and Washington state, and it has faced suits in several other states. 

The company halted sales of mint- and fruit-flavored vape pods in 2019 before the FDA banned most flavored variants in early 2020. According to the Centers for Disease Control and Prevention, nearly 85 percent of young people who tried e-cigarettes said they used flavored varieties. However, vaping has become less popular among teens overall, according to data from 2021. In 2019, Juul revealed a new, connected version of its vape pen that can verify a user’s identity in an attempt to prevent underage use. 

Update 6/23 12:50PM ET: Juul Labs’ chief regulatory officer Joe Murillo provided Engadget with the following statement:

We respectfully disagree with the FDA’s findings and decision and continue to believe we have provided sufficient information and data based on high-quality research to address all issues raised by the agency.
In our applications, which we submitted over two years ago, we believe that we appropriately characterized the toxicological profile of JUUL products, including comparisons to combustible cigarettes and other vapor products, and believe this data, along with the totality of the evidence, meets the statutory standard of being appropriate for the protection of the public health.
We intend to seek a stay and are exploring all of our options under the FDA’s regulations and the law, including appealing the decision and engaging with our regulator. We remain committed to doing all in our power to continue serving the millions of American adult smokers who have successfully used our products to transition away from combustible cigarettes, which remain available on market shelves nationwide.

中高年の片足立ち能力、寿命と関係か

10秒間の片足立ちができない高齢者は、10年以内に死亡するリスクがおよそ2倍になるとの研究結果が発表された/microgen/iStockphoto/Getty Images (CNN) 10秒間の片足立ちができない高齢者は、10年以内に死亡するリスクがほぼ2倍になる――。そんな研究結果が21日、英スポーツ医学誌に発表された。 この単…

なぜエンジニアが認知症フレンドリーテックについて知るべきなのか

煽るようなタイトルですいません。 近い将来ほとんどのエンジニアにとって認知症についての知識は避けて通れないものになると確信しているためこの記事を書いています。 最大の理由は、「日本社会全体の高齢化に伴って、顧客の多くも認知症となるから」です。 実は1ヶ月ほど前にも認知症フレンドリーテックに関する記事…